Skip to contentSIMULGENCEQuantum LabLab

Pharmacology / Receptor states

Cetirizine: what an H1 antihistamine changes

H1 inverse agonism explains selected symptom relief. Drowsiness and rare severe itching after stopping long-term use are reported adverse effects.

Enter the explanation
Conceptual editorial illustration: A large membrane receptor rendered as an intricate translucent molecular gateway, with one fitted antagonist-shaped conceptual blocker and a separate interrupted downstream signaling path.Mechanism / Evidence / Constraints
Simulgence5 minute read Visual analysisExplore Biology

01 / A specific target

Cetirizine changes the response to histamine.

Cetirizine targets H1 receptors and can relieve allergic sneezing, itching and runny nose. It also treats hives when indicated. It does not remove allergens, eradicate infection or suppress the entire immune system.[1]

Histamine acts through several receptor types. Favoring an inactive H1 state does not abolish histamine synthesis, block every histamine receptor or prevent release of all allergic mediators.

Receptor pharmacology

H1 activity and histamine release are distinct.

MAST CELLHistaminereleased signalH1 RECEPTORCetirizine favors an inactive receptor conformation.

Mast cells can release histamine. Histamine activates H1 receptors; cetirizine stabilizes an inactive H1 receptor state and reduces responses without stopping all histamine release.

A conceptual distinction. Receptor shapes and molecular sizes are illustrative.

02 / From allergen to symptoms

An inverse agonist favors an inactive state.

In an immediate allergic response, an allergen can cross-link IgE bound to mast cells, helping trigger release of histamine and other mediators. Histamine acting at H1 receptors contributes to effects including itch, vascular permeability and sensory-nerve activation. Those processes help explain the watery, itchy symptoms an H1 medicine can relieve.

Receptors are dynamic proteins that can occupy different conformations. A neutral antagonist blocks an agonist’s action without changing basal receptor activity in the simple model. An inverse agonist also reduces constitutive activity by favoring an inactive conformation. Experiments with human H1 receptors demonstrated inverse agonism by cetirizine and several other clinically used antihistamines.[2]

Receptor pharmacology does not establish a clinical outcome. Binding affinity, tissue exposure and trial results are separate evidence; expression-system findings establish a mechanism, while trials measure outcomes and labeling reports adverse effects.

03 / Peripheral does not mean impossible in the brain

Drowsiness remains possible.

Cetirizine is often described as a second-generation or less-sedating antihistamine. Compared with many older H1 drugs, it has more limited brain penetration. Nonetheless, drowsiness can occur. Product labeling reports additive drowsiness with alcohol, sedatives and tranquilizers.[3]

Brain histamine signaling contributes to wakefulness, so central H1 blockade can cause sedation. Response varies with factors including kidney function, age, other medicines and formulation. Receptor selectivity alone does not predict an individual response.

Symptom relief

Reduced itch or sneezing is compatible with a useful H1 effect. It does not prove that the underlying trigger has disappeared.

Different mechanism

A decongestant, corticosteroid or epinephrine has different targets and purposes. These medicines are not interchangeable because each can appear in allergy care.

04 / Reported adverse effect

Post-discontinuation itching after long-term use

In 2025 the FDA required a warning about rare but severe itching after stopping long-term oral cetirizine or levocetirizine. Reports typically followed daily use for months or years and began within days of stopping. Spontaneous reports identify a safety concern but do not provide a reliable incidence rate for everyone using the medicine.[4]

Itching after stopping has multiple possible explanations, including recurrence of the original condition. The FDA warning records a rare reported pattern; spontaneous reports do not establish its mechanism, incidence or a single causal pathway.[4]

Sources & further reading

Follow the evidence.

  1. 01
  2. 02
    Bakker et al. (2000): H1 Receptor Constitutive Activity and Inverse Agonism

    Receptor-expression experiment; includes cetirizine.

  3. 03
    DailyMed: Cetirizine Hydrochloride Product Label

    Official labeling on drowsiness and additive sedation.

  4. 04